Quick Answer
Neuphoria Therapeutics Inc. reported Shares Outstanding of 1.98 million shares for fiscal year 2025.
Neuphoria Therapeutics Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 1.98M | +79.2% |
| 2024 | 1.10M | -99.9% |
| 2023 | 1.47B | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | 5.38M | +230.2% | +128.1% |
| September 30, 2025 | 2.36M | -99.9% | +19.2% |
| June 30, 2025 | 1.98M | +79.2% | +6.7% |
| March 31, 2025 | 1.85M | — | +13.8% |
| December 31, 2024 | 1.63M | — | -99.9% |
| September 30, 2024 | 3.12B | — | +282308.8% |
| June 30, 2024 | 1.10M | — | — |
- Neuphoria Therapeutics Inc. showed an increase of +79.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2023–2025 period, Neuphoria Therapeutics Inc.’s shares outstanding has declined by 99.9% (from 1.47 billion shares to 1.98 million shares).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: